Avidity Biosciences Inc (RNA)

May 02, 2025

Avidity Biosciences chief program officer sells $190k in stock - Investing.com

May 02, 2025

Apr 30, 2025

Avidity Biosciences appoints Deloitte as new auditor By Investing.com - Investing.com Canada

Apr 30, 2025

Apr 29, 2025

Avidity Biosciences appoints Deloitte as new auditor - Investing.com

Apr 29, 2025

Apr 27, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 27, 2025

Apr 22, 2025

Avidity Biosciences' RNA Drug for DM1 Gains Orphan Status in Jap - GuruFocus

Apr 22, 2025

Apr 21, 2025

Avidity Biosciences Expands Team with 33 New Hires, Grants $10M+ in Equity Incentives - Stock Titan

Apr 21, 2025

Apr 18, 2025

Avidity Biosciences Plans First BLA Submission and Accelerates Commercialization Preparations for Three Rare Muscle Disease Programs in 2025 (PR Newswire) - Aktiellt

Apr 18, 2025

Apr 09, 2025

Beyond The Numbers: 13 Analysts Discuss Avidity Biosciences Stock - Benzinga

Apr 09, 2025

Apr 08, 2025

Japan grants Avidity’s DM1 drug Orphan status By Investing.com - Investing.com South Africa

Apr 08, 2025

Apr 08, 2025

Avidity Biosciences Receives Orphan Drug Designation in Japan for Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1 - StreetInsider

Apr 08, 2025

Apr 08, 2025

Avidity Biosciences Receives Orphan Drug Designation in Japan fo - GuruFocus

Apr 08, 2025

Apr 08, 2025

Avidity Says Japan Grants Orphan Drug Status to Del-Desiran for Myotonic Dystrophy Type 1 - marketscreener.com

Apr 08, 2025

Apr 08, 2025

Japan grants Avidity's DM1 drug Orphan status By Investing.com - Investing.com India

Apr 08, 2025

Apr 08, 2025

Japan grants Avidity's DM1 drug Orphan status - Investing.com

Apr 08, 2025

Apr 08, 2025

Avidity Biosciences Receives Orphan Drug Designation In Japan For Delpacibart Etedesiran - MarketScreener

Apr 08, 2025

Apr 07, 2025

Myotonic Dystrophy Pipeline Analysis and Clinical Trials - openPR.com

Apr 07, 2025

Apr 06, 2025

Avidity Biosciences chief program officer sells shares worth $206,799 - MSN

Apr 06, 2025

Apr 06, 2025

Avidity Biosciences CFO sells $93,985 in stock - MSN

Apr 06, 2025

Apr 05, 2025

Avidity Biosciences (RNA): Among Unstoppable Stocks That Could Double Your Money - MSN

Apr 05, 2025

Apr 03, 2025

Avidity Biosciences’ chief program officer sells $163k in stock - Investing.com India

Apr 03, 2025

Apr 03, 2025

Avidity Biosciences’ chief program officer sells $163k in stock By Investing.com - Investing.com UK

Apr 03, 2025

Apr 03, 2025

Avidity Biosciences (RNA) Soars 11.3%: Is Further Upside Left in the Stock? - Nasdaq

Apr 03, 2025

Apr 02, 2025

When the Price of (RNA) Talks, People Listen - news.stocktradersdaily.com

Apr 02, 2025

Apr 02, 2025

Avidity Biosciences : to Present at the Virtual Chardan 4th Annual Genetic Medicines Conference 2020 - marketscreener.com

Apr 02, 2025

Apr 01, 2025

Avidity Biosciences to Participate in Upcoming Investor Conference - StreetInsider

Apr 01, 2025

Mar 31, 2025

Avidity Biosciences’s SWOT analysis: stock poised for growth amid clinical progress - Investing.com India

Mar 31, 2025

Mar 31, 2025

Cantor Fitzgerald maintains $96 target on Avidity Biosciences stock - Investing.com Australia

Mar 31, 2025

Mar 31, 2025

Cantor Fitzgerald maintains $96 target on Avidity Biosciences stock By Investing.com - Investing.com Canada

Mar 31, 2025

Mar 31, 2025

Avidity Biosciences’s SWOT analysis: stock poised for growth amid clinical progress By Investing.com - Investing.com South Africa

Mar 31, 2025

Mar 31, 2025

Avidity Completes Enrollment in Del-brax Trial's Biomarker Group for Facioscapulohumeral Muscular Dystrophy - MarketScreener

Mar 31, 2025

Mar 31, 2025

Avidity Biosciences Completes Enrollment in Biomarker Cohort in Phase 1/2 FORTITUDE™ Trial for Delpacibart Braxlosiran (del-brax) in People Living with Facioscapulohumeral Muscular Dystrophy - StreetInsider

Mar 31, 2025

Mar 31, 2025

Avidity Biosciences Completes Enrollment in Biomarker Cohort in Phase 1/2 FORTITUDE™ Trial for Delpacibart Braxlosiran (del-brax) in People Living with Facioscapulohumeral Muscular Dystrophy – Company AnnouncementFT.com - Financial Times

Mar 31, 2025

Mar 30, 2025

11 Best Gene Therapy Stocks to Buy According to Analysts - Insider Monkey

Mar 30, 2025

Mar 29, 2025

EFG Asset Management North America Corp. Purchases 58,198 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA) - MarketBeat

Mar 29, 2025

Mar 26, 2025

The Risk/Reward Of Avidity Biosciences And Its 2 Promising Programs (NASDAQ:RNA) - Seeking Alpha

Mar 26, 2025

Mar 22, 2025

Avidity Biosciences chief scientific officer sells $365,867 in stock By Investing.com - Investing.com Australia

Mar 22, 2025

Mar 22, 2025

Avidity Biosciences CFO Michael MacLean sells $246,424 in stock By Investing.com - Investing.com Australia

Mar 22, 2025

Mar 22, 2025

Avidity Biosciences Inc Stock: Leadership Sells Shares Amid Clinical Success - Sharewise

Mar 22, 2025

Mar 21, 2025

Avidity Biosciences chief HR officer sells $241,583 in stock By Investing.com - Investing.com Australia

Mar 21, 2025

Mar 21, 2025

Avidity Biosciences chief HR officer sells $241,583 in stock - Investing.com India

Mar 21, 2025

Mar 21, 2025

Avidity Biosciences CEO Sarah Boyce sells $979,563 in stock - Investing.com India

Mar 21, 2025

Mar 21, 2025

Avidity Biosciences CEO Sarah Boyce sells $979,563 in stock By Investing.com - Investing.com South Africa

Mar 21, 2025

Mar 21, 2025

Avidity Biosciences chief scientific officer sells $365,867 in stock - Investing.com

Mar 21, 2025

Mar 21, 2025

Avidity Biosciences chief medical officer sells $297,490 in stock - Investing.com

Mar 21, 2025

Mar 21, 2025

Avidity Biosciences Executives Sell Shares for Tax Obligations - TradingView

Mar 21, 2025

Mar 21, 2025

Avidity Biosciences Executives Sell Shares to Cover Tax Obligations - TradingView

Mar 21, 2025

Mar 21, 2025

Avidity Biosciences announces inducement grants under Nasdaq listing rule 5635(C)(4) - Marketscreener.com

Mar 21, 2025